Efficacy and Safety of the Arsenic Trioxide/Lipiodol Emulsion in the Transcatheter Arterial Chemoembolization Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

Table 4

Factors affecting PFS and OS.

Parameters	PFS				OS
	HR	95% CI			HR	95% CI
		Lower	Higher			Lower	Higher
Univariate Cox regression
Age (>60 vs. ≤60)	0.927	0.591	1.454	0.741	1.481	0.936	2.346	0.094
Child–Pugh (A vs. B)	1.059	0.676	1.658	0.803	1.198	0.752	1.909	0.447
Cirrhosis (yes vs. no)	1.210	0.768	1.907	0.410	1.061	0.671	1.679	0.800
AFP level (≤400 ng/mL vs. >400 ng/mL)	1.155	0.737	1.808	0.530	1.954	1.204	3.171	0.007
HBV infection (yes vs. no)	2.088	1.284	3.394	0.003	1.209	0.763	1.917	0.419
Tumour burden (≤50% vs. >50%)	13.089	3.898	13.089	<0.001	6.576	3.756	11.512	<0.001
PVTT (absent vs. present)	6.081	3.378	10.946	<0.001	4.854	2.787	8.455	<0.001
Multivariate Cox regression
Age (>60 vs. ≤60)	0.726	0.441	1.195	0.209	2.206	1.306	3.728	0.003
Child–Pugh (A vs. B)	1.012	0.594	1.724	0.964	1.577	0.943	2.638	0.082
Cirrhosis (yes vs. no)	1.376	0.831	2.278	0.215	1.360	0.798	2.317	0.258
AFP level (≤400 ng/mL vs. >400 ng/mL)	1.233	0.711	2.139	0.456	0.923	0.544	1.564	0.765
HBV infection (yes vs. no)	1.370	0.787	2.386	0.265	1.313	0.750	2.300	0.341
Tumour burden (≤50% vs. >50%)	19.155	9.255	39.647	<0.001	15.484	7.865	30.484	<0.001
PVTT (absent vs. present)	15.714	7.208	34.257	<0.001	12.731	6.188	26.194	<0.001

OS, overall survival; HR, hazard ratio; CI, confidence interval; PFS, progression-free survival; AFP, alpha-fetoprotein; HBV, hepatitis B virus; PVTT, portal vein tumor thrombus.